NASDAQ:AFMD
Affimed N.V. Stock News
$4.88
+0 (+0%)
At Close: Apr 25, 2024
Affimed to Present at the H.C. Wainwright Annual Global Investment Conference
06:30am, Thursday, 07'th Sep 2023
HEIDELBERG, Germany, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, an
Surprise! These 3 Penny Stocks Have Wall Street's Seal of Approval.
06:00am, Wednesday, 23'rd Aug 2023
Although relative few investors – let alone analysts hired by top research institutions – give much thought to low-volume speculative securities, the concept of top Wall Street penny stocks is not
Affimed N.V. (AFMD) Reports Q2 Loss, Misses Revenue Estimates
09:15am, Thursday, 10'th Aug 2023
Affimed N.V. (AFMD) came out with a quarterly loss of $0.22 per share in line with the Zacks Consensus Estimate.
3 Cheap Stocks to Buy Under $1 in August 2023
04:51pm, Friday, 04'th Aug 2023
The world of penny stocks is rife with potential pitfalls to avoid. Many firms trading at those prices are manipulated by actors with bad intent.
Affimed to Report Second Quarter 2023 Financial Results & Corporate Update on August 10, 2023
06:30am, Thursday, 03'rd Aug 2023
HEIDELBERG, Germany, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, ann
Affimed to Present at the 2023 Jefferies Healthcare Conference
06:30am, Tuesday, 30'th May 2023
HEIDELBERG, Germany, May 30, 2023 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back thei
Affimed N.V. (AFMD) Q1 2023 Earnings Call Transcript
12:36pm, Tuesday, 23'rd May 2023
Affimed N.V. (NASDAQ:AFMD ) Q1 2023 Earnings Conference Call May 23, 2023 8:30 AM ET Company Participants Alex Fudukidis - Director of Investor Relations Adi Hoess - Chief Executive Officer Andreas Ha
Affimed N.V. (AFMD) Reports Q1 Loss, Lags Revenue Estimates
08:53am, Tuesday, 23'rd May 2023
Affimed N.V. (AFMD) came out with a quarterly loss of $0.23 per share versus the Zacks Consensus Estimate of a loss of $0.22.
Affimed to Report First Quarter 2023 Financial Results & Corporate Update on May 23, 2023
06:30am, Tuesday, 16'th May 2023
HEIDELBERG, Germany, May 16, 2023 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, anno
Affimed N.V. (AFMD) Reports Q4 Loss, Tops Revenue Estimates
11:45am, Thursday, 23'rd Mar 2023 Zacks Investment Research
Affimed N.V. (AFMD) delivered earnings and revenue surprises of -15.79% and 45.75%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Affimed Reports 2022 Financial Results and Operational Progress
10:30am, Thursday, 23'rd Mar 2023 GlobeNewswire Inc.
HEIDELBERG, Germany, March 23, 2023 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed” or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back t
Affimed N.V. (AFMD) Reports Q4 Loss, Tops Revenue Estimates
09:08am, Thursday, 23'rd Mar 2023
Affimed N.V. (AFMD) delivered earnings and revenue surprises of -15.79% and 45.75%, respectively, for the quarter ended December 2022.
Liquidia Technologies, Inc. (LQDA) Reports Q4 Loss, Tops Revenue Estimates
11:55am, Thursday, 16'th Mar 2023 Zacks Investment Research
Liquidia Technologies, Inc. (LQDA) delivered earnings and revenue surprises of 47.06% and 46.73%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for th
Affimed to Report Full Year 2022 Financial Results & Corporate Update on March 23, 2023
10:30am, Thursday, 16'th Mar 2023 GlobeNewswire Inc.
HEIDELBERG, Germany, March 16, 2023 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer,
Affimed to Report Full Year 2022 Financial Results & Corporate Update on March 23, 2023
06:30am, Thursday, 16'th Mar 2023
HEIDELBERG, Germany, March 16, 2023 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, an